Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.

Abstract: Provided are cannabinoid-loaded, dilutable microemulsion formulations with low oil content including oleic acid and linoleic acid.

Abstract: Methods of determining the origin of cell free DNA (cfDNA), for detecting death of a cell type or tissue in a subject, for determining a cellular state of a cell as it died, and combinations thereof, are provided. As are computer program products for doing same.

Abstract: A system and method of non-invasive diagnosis of a condition in a subject may include obtaining, from a medical scanning device, a three-dimensional (3D) scan of the subject, said scan comprising a plurality of quantitative or semi-quantitative voxel values; segmenting the scan, to obtain a segmented region of interest (ROI) of the subject; performing a singular value decomposition (SVD) of the ROI, to determine at least one axis of the ROI in the SVD space; and analyzing the voxel values along the at least one axis, to diagnose a condition of the subject. Analysis of the voxel values may include calculating a quantitative function of voxel values along the at least one axis; comparing the calculated quantitative function to a reference quantitative function; and diagnosing or predicting a condition of the subject, based on the comparison.

Abstract: A spin-selective conduction structure comprises a crystal having a monolayer of metal atoms between two layers of chiral organic molecules. Each metal atom is coupled to two chiral organic molecules, one at each layer, wherein a chirality of organic molecules in one of the two layers is the same as a chirality of organic molecules in another one of the two layers.

Abstract: The present invention is directed to a method for determining a subject is afflicted with or having increased risk of developing an alpha-synuclein-associated disease or disorder, Parkinson's disease, or both. The method further includes administering to the subject determined as being afflicted with or having increased risk of developing an alpha-synuclein-associated disease or disorder a therapeutically effective amount of an agent characterized by being capable of decreasing signaling transduced by a member of PI4,5P2 PI3,4P2, PI3,5P2, PI3,4,5P3, PI3P, PI4P signal transduction pathway.

Abstract: A method of modifying a glycosylation pattern of a polypeptide-of-interest in a plant or plant cell is provided. The method comprising expressing in a plant or plant cell transformed to express at least one glycosidase in a subcellular compartment, a nucleic acid sequence encoding the polypeptide-of-interest, such that the at least one glycosidase and the polypeptide-of-interest are co-localized to the subcellular compartment of the plant or plant cell, thereby modifying the glycosylation pattern of the polypeptide-of-interest in the plant or plant cell.

Abstract: Isolated polypeptides of CD44 are provided. Accordingly, there is provided an isolated polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-3. Also provided is an isolated end-capping modified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-3, wherein the modified polypeptide comprises an anti-inflammatory activity. Also provided are compositions of matter, fusion proteins and pharmaceutical compositions and their use in the treatment of inflammatory disease.

Abstract: Methods, compositions and kits for reducing renal tissue toxicity in a subject caused by a kidney damaging agent are provided. The methods comprise administering to the subject: (i) a kidney damaging agent; (ii) a PPARA activator; and (iii) an inhibitor of a cellular pathway selected from the group consisting of C/EBP, PPARG, ER stress, GLUT2 and SGLT1/2; or (i) a kidney damaging agent; (ii) a SGLT2 inhibitor; and (iii) a PPARA activator, a C/EBP inhibitor, a PPARG inhibitor, or an ER stress inhibitor.

Abstract: An electronic device element is described which is flexible, bendable or twistable without substantial degradation in optical or electrical properties. The electronic device element includes an optically transparent film constructed of a recombinant re-silin-CBD protein bound to cellulose nanocrystals (CNC). The recombinant resilin-CBD protein includes a Clostridium-derived cellulose-binding domain fused to resilin. The electronic device element may be a flexible display or flexible electronics element.

Abstract: Disclosed are peptides that specifically bind to neutrophils and uses thereof for neutrophil-targeted delivery of drugs or diagnostic agents in medical conditions including cancer as well as infectious, inflammatory and autoimmune diseases or disorders.

Abstract: Devices and method for determining a pupil size of a subject having closed eyelids.

Abstract: The invention disclosed herein concerns a novel class of compounds suitable for the treatment of neurodegenerative diseases, such as Parkinson’s Disease.

Abstract: Methods of treating coronavirus infection, or decreasing the risk of symptomatic infection, by administering a peroxisome proliferator-activated receptor alpha (PPARA) agonist or an inositol-requiring enzyme 1 (IRE1) pathway inhibitor are provided.

Abstract: Provided is a composite of a CNT assembly including a plurality of carbon nanotubes (CNTs) and at least one metalcone material, the composite being tunable, by a vapor phase chemical modification, to adopt one or more collective properties selected from mechanical, chemical, physical or electrical properties.

Abstract: A system and method are presented, for monitoring and/or imaging of a sample. The system comprises: a light unit configured for illuminating the sample in at least two different wavelength ranges; a collection unit configured for collecting a light emitted from the sample in at least a third wavelength range and directing said emitted light towards at least one detector; and an activation unit configured for providing activation signal to selectively activate at least a portion of fluorescent substance in the sample; and a processing circuitry configured for operating the light unit to determine a selected temporal illumination profile of said at least two different wavelength ranges and for operating the activation unit for controllable activation.

Abstract: The technology disclosed herein concerns compounds capable of binding to CB1Rs in the periphery and not in the CNS.

Abstract: Provided is a perovskite-based photovoltaic device including a layered scaffold material and at least one perovskite material interpenetrating the layered scaffold, wherein the at least one perovskite layer is removable and regenerable.

Abstract: The present invention provides processes for producing food products, particularly juice beverages, with reduced sugar content enriched with dietary fibers and the food products produced. The processed food products are low in calories while preserving the palatable test of the starting material, and contain beneficial amount of dietary fibers. The processed food product further contains sorbitol and gluconic acid.

Abstract: The invention relates to a process for treating food, in particular for curing meat, comprising adding to the food a compound of Formula III, which is a derivative of S-nitroso-cysteine. Use of the compound of Formula III as food preservative and compositions for curing meat are also provided by the invention.